Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Tempest Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0.65
0.3
Cost of revenue
5.4
0.79
Gross profit
-4.75
-0.5
Research and development
21.6
18.3
14.4
27.8
14.4
17.2
22.5
17.5
28.5
12.6
Selling, general and administrative
49.2
27.7
General and administrative
5.96
8.69
17.6
4.91
9.82
12.1
11.7
13.6
14
Operating expenses
81.7
50.9
Operating income
-81
-84.3
-26.9
-45.4
-19.3
-27
-34.6
-29.2
-42
-26.6
Interest expense
0.29
0.13
0
1.28
1.62
1.45
1.32
0.21
Other non-operating income
-0.16
-0.04
0.09
-1.32
-1.07
-0.33
0.18
0.31
Pre-tax income
-82.1
-50.9
Income tax
0.2
0.07
0
0
0
0
0
0
Net income to minority interests
-0.01
0.02
0
Net income
-82.3
-84.6
-27.2
-44.6
-19.2
-28.3
-35.7
-29.5
-41.8
-26.3
EBITDA
-78.8
-82.7
-26.8
-45.3
-19
-26.6
-34
-28.8
-41.6
-26.3
EPS, basic
-159,218.00
-88,938.00
-4,859.00
-898.20
-533.39
-97.11
-40.17
-24.83
-19.50
-6.33
EPS, diluted
-159,218.00
-88,938.00
-4,859.00
-898.20
-533.39
-97.11
-40.17
-24.83
-19.50
-6.33
Shares, basic (weighted)
0
0
0.01
0.05
0.04
0.29
0.89
1.19
2.15
4.15
Shares, diluted (weighted)
0
0
0.01
0.05
0.04
0.29
0.89
1.19
2.15
4.15
Dividend per share
0.00
0.00
0.00
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
43.9
17.6
73.3
62.5
18.8
51.8
31.2
39.2
30.3
7.71
Short-term investments
70.5
51.5
0
Other current assets
2.06
1.08
3.37
6.34
0.06
0.55
0.26
0.1
0.54
0.36
Total current assets
116
19.7
83.4
71.1
19.8
69
33
40.4
31.5
8.27
Property, plant and equipment
5.57
3.11
1.11
1.11
1.06
0.84
0.89
0.61
Lease right-of-use assets
3.33
1.88
3.05
11.7
9.95
8.64
7.54
Other non-current assets
0.02
0.07
0.21
0.51
0.05
0.11
0.43
0.45
0.49
0.52
Total assets
123
19.8
84.1
75
22.9
73.2
46.1
51.6
41.5
16.9
Accounts payable
2.18
1.3
2
1.5
1.07
0.99
1.11
0.85
2.45
1.04
Accrued liabilities
11
2.62
7.63
9.07
0.67
1.59
2.96
1.67
2.73
0.94
Short-term debt
0.17
0.19
0.21
0.24
4.29
6.35
0
Total current liabilities
13.2
4.09
9.82
12.5
3.22
20
7.28
9.41
14.2
3.31
Long-term debt
0.6
0.38
0.17
0
15.1
10.4
6.26
0
Lease liabilities
2.4
1.73
2.03
10.3
9.16
8.14
6.95
Other non-current liabilities
1.12
0.75
0.75
0.02
0
Total liabilities
14.3
4.83
11
15.1
4.95
37.1
28
24.8
22.4
10.3
Total debt
0.6
0.57
0.38
0.24
15.1
10.4
10.5
6.4
0
Paid-in capital
358
6.19
235
267
2.97
136
154
192
226
240
Retained earnings
-250
-137
-164
-209
-71.8
-100
-136
-165
-207
-233
Other comprehensive income
-0.06
0.01
0.15
0.17
0.45
Shareholders' equity
108
-131
71
-50.4
-68.8
36.1
18.1
26.8
19.1
6.67
Minority interests
2.17
2.17
1.32
0.67
Total equity
-51.2
-129
73.1
59.9
-68.8
36.1
18.1
26.8
19.1
6.67
Total liabilities and equity
123
19.8
84.1
75
22.9
73.2
46.1
51.6
41.5
16.9
Shares outstanding
0
0
0.05
0.07
0.04
0.53
0.81
1.7
3.38
4.93
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-82.3
-84.6
-27.2
-44.6
-19.2
-28.3
-35.7
-29.5
-41.8
-26.3
Depreciation and amortization
2.24
1.65
0.03
0.1
0.34
0.37
0.64
0.38
0.39
0.27
Stock-based compensation
9.22
6.89
1.43
4.32
0.45
1.11
1.56
2.55
5.3
3.12
Change in payables
-1.18
0.07
Cash from operations
-61.7
-20.3
-23.6
-41.2
-19
-26
-31.1
-27.4
-33
-26.8
Capital expenditures
-2.59
-0
-0.04
-0.4
-0.05
-0.14
-0.56
-0.17
-0.44
0
Acquisitions
0.46
-0.52
0
Purchases of investments
-82.7
-68.9
Sales and maturities of investments
2.49
4.39
0
Cash from investing
8.29
0.46
1.93
3.99
-0.01
-0.1
-0.56
-0.17
-0.44
0
Debt issued
6
0
15
Debt repaid
-10
-0.17
-0.18
-0.11
-4.74
-4.4
-6.43
Stock issued
53.9
0
0
26.7
0
33.4
8.86
35.6
28.6
6.05
Cash from financing
54.1
-4.46
77.7
26.9
34.6
59.1
11.4
35.6
24.5
4.26
Exchange rate effect
0.02
0.12
0.03
0.22
Net change in cash
-24.3
56.1
-10.3
-24.9
33
-20.2
8.08
-8.96
-22.6
Free cash flow
-64.3
-20.3
-23.7
-41.6
-19.1
-26.1
-31.6
-27.5
-33.5
-26.8
Interest paid
0.21
0
0.95
1.54
1.25
1.18
0.19
Income taxes paid
0
0
0.02
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $0.83 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on assets (ROA)
-420.1%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
-65.1%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-28.3%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
-59.2%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-28.4%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-5.8%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
93.3%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
67.2%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
158.4%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.38x
Current assets / current liabilities.
Quick ratio
0.18x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.18x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
FCF per share
-$1.36
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$1.36
Cash from operations / diluted weighted shares.
Book value per share
-$0.07
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
FCF yield
-156.5%
Free cash flow / market cap.
Earnings yield
-305.5%
Net income / market cap (the inverse of P/E).
Was Tempest Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $26.3M.
How much free cash flow did Tempest Therapeutics, Inc. generate in fiscal 2025?
Cash from operations of $26.8M minus capital expenditures of $0.0 left free cash flow of -$26.8M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.